Payment overview · 2025
General Payments
$810.59
7 reported records · 6 companies
Healthcare provider profile · identity verified
Judy Chiu, DO
Allopathic & Osteopathic Physicians|Family Medicine · CANTON, CT · NPI 1982865101
Verified facts
What the public records show
CMS Open Payments records show Judy Chiu, DO received $810.59 in general payments during 2025 across 7 reported records.
Axsome Therapeutics, Inc. accounted for 28.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $227.08 | 28.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $140.00 | 17.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $130.54 | 16.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $124.98 | 15.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $122.08 | 15.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.91 | 8.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $810.59 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $227.08 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $140.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $130.54 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $122.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 323 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 205 | 69 |
| Alprazolam | Alprazolam | 134 | 37 |
| Lorazepam | Lorazepam | 113 | 33 |
| Omeprazole | Omeprazole | 89 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 33 |
| Lisinopril | Lisinopril | 87 | 28 |
| Sertraline Hcl | Sertraline Hcl | 82 | 24 |
| Amlodipine Besylate | Amlodipine Besylate | 77 | 29 |
| Losartan Potassium | Losartan Potassium | 77 | 24 |
| Meloxicam | Meloxicam | 76 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 69 | 13 |
| Simvastatin | Simvastatin | 68 | 21 |
| Azithromycin | Azithromycin | 63 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 32 |
| Tramadol Hcl | Tramadol Hcl | 56 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 50 | 25 |
| Synthroid | Levothyroxine Sodium | 50 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 16 |
| Trazodone Hcl | Trazodone Hcl | 48 | 14 |
| Montelukast Sodium | Montelukast Sodium | 47 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Gabapentin | Gabapentin | 43 | 19 |
| Allopurinol | Allopurinol | 42 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 11 |
| Diazepam | Diazepam | 40 | suppressed |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 38 | 16 |
| Liothyronine Sodium | Liothyronine Sodium | 35 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | 13 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Metformin Hcl | Metformin Hcl | 34 | 13 |
| Prednisone | Prednisone | 34 | 24 |
| Ozempic | Semaglutide | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 11 |
| Valsartan | Valsartan | 32 | 14 |
| Nystatin | Nystatin | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | 13 |
| Atenolol | Atenolol | 28 | 11 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Eliquis | Apixaban | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Furosemide | Furosemide | 17 | 13 |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Lovastatin | Lovastatin | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Clarithromycin Er | Clarithromycin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $810.59 · 7 records | Axsome Therapeutics, Inc. | AIRSUPRA, Auvelity, REPATHA, Veozah, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error